Dr. William Williams reports

BRIACELL RECORDS NEW RESPONDER WITH REMARKABLE IMPROVEMENT OF "EYE-BULGING" METASTATIC TUMOR

Briacell Therapeutics Corp. has provided an update on a new remarkable responder in its phase 2 study of the Bria-IMT combination regimen. Briacell's clinical team reported a patient with extensive metastatic breast cancer who had failed all available therapies. The patient had cancer behind the eye, causing proptosis (eye bulging) and significant pain that were both resolved with Briacell's treatment.

Additional survival updates and clinical data sets on the entire phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium on Dec. 6 and Dec. 7, 2023.

"Responses like this are not often seen in heavily pretreated patients and are especially rare in metastatic disease to the eye," stated Dr. Carmen Calfa, MD, clinical research lead for the breast site disease group at the University of Miami Miller School of Medicine, co-director of the cancer survivorship program at Sylvester Comprehensive Cancer Center and principal clinical investigator of the phase 2 Bria-IMT study. "We were excited to offer her the latest treatments and thrilled to share in her success and joy."

The noted responder, a postmenopausal metastatic breast cancer patient (the remarkable responder), experienced a remarkable improvement of proptosis caused by breast cancer tumours behind the eye, resulting in significant pain reduction in the ocular region. Her disease is characterized as positive for hormone receptor and 3+ for HER2. The woman had extensive metastatic disease (breast cancer tumours that have migrated to other areas of the body), including the bones of the spine, pelvis, sternum, the skull and face, which included proptosis of the right eye, from which the patient was clinically blind in that eye.

The patient was heavily pretreated (seven prior regimens) highlighting the remarkable nature of her response on Briacell's treatment despite her very advanced cancer stage. Her last disease progression was recorded in August, 2023. The patient started on Briacell's Bria-IMT combination therapy on Oct. 4, 2023, and has received only three cycles of therapy. The Bria-IMT combination regimen has been well tolerated and the patient remains on treatment.

Briacell had previously reported a similar case of a remarkable response with 100-per-cent resolution of an eye-bulging orbital tumour. This particular patient had received (and failed) 12 regimens with 16 agents (including 13 chemotherapies) prior to Briacell's treatment, again adding to the remarkable nature of her response.

"We are reporting remarkable clinical responses in patients who were previously thought untreatable, suggesting effectiveness in difficult-to-reach tumours such as those in the bones and the brain," said Dr. William V. Williams, Briacell's president and chief executive officer. "We hypothesize that our Bria-IMT regimen may cross the blood-brain barrier to treat these difficult-to-reach areas, such as the brain, which continues to increase our excitement for our novel cancer immunotherapy. We have seen several patients with central nervous system metastases respond to our therapy and are looking forward to further investigating this unique observation in our pivotal phase 3 study of Bria-IMT combination therapy in advanced metastatic breast cancer."

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.